Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (552)	4/5/1998 6:46:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

Dear Yosi, You're right. In the Matimop website I found (unfortunately undated), PARS lists the timetable for Tamoxifen s follows: ÿSUGGESTED TOPICS FOR R&D COOPERATION, Project No. 1 Project title: Compounds for cancer treatment R&D object of cooperation: Codevelopment of compounds for treatment of breast & other cancer diseases. Potential application of R&D results: Cancer treatment Projected effort Present stage of R&D: preclinical Duration (years): 4 <---Yosi, think this means 2002?? Budget (U$): 30,000 PREFERRED PARTNERS Activity/location Organization type: I ndustry Location: Worldwide Operates in: Worldwide / international Focus of activity:Fully integrated pharmaceutical company Role of potential partner Preferred framework: Bilateral, EC program, Eureka Specific contribution: Financial support of R&D and carrying out advanced clinical studies in return for marketing rights. Partner responsibility: Activity in financial and marketing aspects. --Ariella